Abstract
The authors define the dose-limiting toxicities and the recommended phase II doses of paclitaxel combined with etoposide, without and with filgrastim support. Patients with advanced solid tumors were eligible if they had a performance status of 0 to 2 and normal renal, hepatic, and bone marrow function. Patients with cardiac arrhythmias or congestive heart failure requiring medical therapy were excluded. Prior radiation was allowed only if it involved less than 30% of the marrow-containing skeleton. The dose of etoposide was fixed at 100 mg/m2/d for 3 days beginning on day 1. Paclitaxel was administered over 3 hours on day 4. The dose of paclitaxel was escalated until the maximum tolerated dose (MTD), without and with filgrastim 5 microg/kg (or 300 microg total dose) subcutaneously beginning on day 5, was reached. Treatment cycles were repeated every 21 days. Of 39 patients entered, 37 were evaluable for toxicity and 30 for response. The principal toxicity was neutropenia. Without filgrastim, the MTD of paclitaxel was 150 mg/m2. With filgrastim, the dose of paclitaxel was escalated to 250 mg/m2 in combination with etoposide 100 mg/m2. One episode of pulmonary toxicity was observed. Five patients responded: two with previously t...Continue Reading
References
Jul 11, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B WeissB Leyland-Jones
Jan 4, 1996·The New England Journal of Medicine·W P McGuireM Davidson
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerD Spriggs
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerP Fischer
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R C LilenbaumR L Schilsky
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Apr 1, 1994·Journal of the American College of Nutrition·R B SinghM A Niaz
May 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G P Bodey
Mar 1, 1993·Cancer·B C PestalozziJ A O'Shaughnessy
Aug 1, 1993·Journal of the American College of Nutrition·N B Cummings
Oct 1, 1995·Journal of the American College of Nutrition·J McDougallG A Spiller
Sep 15, 1995·Cancer·V G SchweitzerR G Parker
Jul 1, 1996·Chest·R K RamanathanC P Belani
Sep 1, 1996·American Journal of Respiratory Cell and Molecular Biology·N BerkmanK F Chung
Citations
Mar 10, 2001·Journal of Chemotherapy·L NanniG Lelli
Jun 16, 2004·Cancer·Caio M S Rocha LimaMark R Green
Feb 24, 2001·American Journal of Clinical Oncology·G F FlemingW P McGuire
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseW P McGuire